JP2019519208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519208A5 JP2019519208A5 JP2018559329A JP2018559329A JP2019519208A5 JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5 JP 2018559329 A JP2018559329 A JP 2018559329A JP 2018559329 A JP2018559329 A JP 2018559329A JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- cell
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 77
- 102000036639 antigens Human genes 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 77
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 23
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 23
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- -1 ICOS Proteins 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000003915 cell function Effects 0.000 claims description 4
- 102000043321 human CTLA4 Human genes 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 claims description 2
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 102000024905 CD99 Human genes 0.000 claims description 2
- 108060001253 CD99 Proteins 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 claims description 2
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100040120 Prominin-1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 2
- 230000017274 T cell anergy Effects 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 102000054189 human CD80 Human genes 0.000 claims description 2
- 102000049849 human CD86 Human genes 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201603721TA SG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| SG10201603721T | 2016-05-10 | ||
| PCT/EP2017/058956 WO2017194265A1 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519208A JP2019519208A (ja) | 2019-07-11 |
| JP2019519208A5 true JP2019519208A5 (OSRAM) | 2019-08-22 |
| JP6650537B2 JP6650537B2 (ja) | 2020-02-19 |
Family
ID=58609383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559329A Active JP6650537B2 (ja) | 2016-05-10 | 2017-04-13 | 抗ｃｔｌａ−４抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11267887B2 (OSRAM) |
| EP (1) | EP3455255B1 (OSRAM) |
| JP (1) | JP6650537B2 (OSRAM) |
| KR (1) | KR20190015715A (OSRAM) |
| CN (1) | CN109563165B (OSRAM) |
| AU (1) | AU2017262448A1 (OSRAM) |
| CA (1) | CA3023787A1 (OSRAM) |
| SG (2) | SG10201603721TA (OSRAM) |
| TW (1) | TW201739763A (OSRAM) |
| WO (1) | WO2017194265A1 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2785692T3 (en) | 2011-12-01 | 2018-01-02 | Chemocentryx Inc | SUBSTITUTED ANILINES AS CCR (4) ANTAGONISTS |
| NZ738068A (en) | 2015-05-06 | 2019-07-26 | Snipr Tech Ltd | Altering microbial populations & modifying microbiota |
| HUE050750T2 (hu) | 2015-05-29 | 2021-01-28 | Agenus Inc | CTLA-4 elleni antitestek és eljárások alkalmazásukra |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| SG11202001604UA (en) * | 2017-09-21 | 2020-04-29 | Eucure Beijing Biopharma Co Ltd | Anti-ctla4 antibodies and uses thereof |
| EP3707162A1 (en) | 2017-11-10 | 2020-09-16 | Agency for Science, Technology and Research | Il2rbeta/common gamma chain antibodies |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP2021512635A (ja) * | 2018-02-12 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的とするキメラ抗原受容体 |
| US10760075B2 (en) * | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| AU2019269628A1 (en) * | 2018-05-17 | 2020-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| SG11202101454PA (en) | 2018-08-29 | 2021-03-30 | Chemocentryx Inc | Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| TW202039557A (zh) | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| MX2021007848A (es) | 2018-12-27 | 2021-10-26 | Gigagen Inc | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN110343180B (zh) * | 2019-07-25 | 2021-03-30 | 北京免疫方舟医药科技有限公司 | 抗ctla-4抗体及其应用 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN116249715A (zh) * | 2020-06-11 | 2023-06-09 | 南特生物科学公司 | 抗ctla4单克隆抗体和嵌合抗原受体 |
| JP7783840B2 (ja) * | 2020-07-02 | 2025-12-10 | ギガジェン，インコーポレイティッド | 抗ｃｔｌａ－４結合タンパク質及びその使用方法 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| RU2757418C1 (ru) * | 2021-03-04 | 2021-10-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Тетрадекапептидный антагонист взаимодействия CTLA-4 c B7-1 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2025137321A1 (en) * | 2023-12-21 | 2025-06-26 | Fenwal, Inc. | System and method for affinity cell selection |
| EP4599843A1 (en) | 2024-02-09 | 2025-08-13 | Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau | Car and modified cd200r combination |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0615451T3 (da) | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| MX2007011064A (es) | 2005-03-23 | 2008-02-19 | Genmab As | Anticuerpos contra cd38 para tratamiento de mieloma multiple. |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| ES2613957T3 (es) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Anticuerpos contra ERBB2 |
| EP2087114B1 (en) | 2006-11-13 | 2013-05-29 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using sirna molecules directed against cd24 |
| BRPI0808055A2 (pt) | 2007-02-16 | 2013-07-30 | Merrimack Pharmaceuticals Inc | anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, composiÇço, Ácido nucleico isolado, vetor de expressço, cÉlula hospedeira, hibridoma, kit, uso de um anticorpo monoclonal isolado ou porÇço do mesmo que se liga ao antÍgeno, mÉtodo para diagnosticar um cÂncer associado com erbb3 em um paciente, e, anticorpo |
| TW200938224A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX2012013702A (es) | 2010-05-26 | 2013-03-21 | Univ Minnesota | Anticuerpos anti-cd133 de fragmento variable de cadena individual y usos de los mismos. |
| ME02678B (me) | 2010-08-23 | 2017-06-20 | Univ Texas | Antitijela na ox-40 i postupci njihove primjene |
| EP2703486B1 (en) | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| ES2694153T3 (es) | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 y usos de los mismos |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| JP6368308B2 (ja) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | 癌の診断および治療のためのｖｉｓｔａ調節剤 |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| CA2894689A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| WO2014160627A1 (en) | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| PL3508502T3 (pl) | 2013-09-20 | 2023-07-17 | Bristol-Myers Squibb Company | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka |
| US10273301B2 (en) | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
-
2016
- 2016-05-10 SG SG10201603721TA patent/SG10201603721TA/en unknown
-
2017
- 2017-04-13 WO PCT/EP2017/058956 patent/WO2017194265A1/en not_active Ceased
- 2017-04-13 TW TW106112375A patent/TW201739763A/zh unknown
- 2017-04-13 US US16/099,652 patent/US11267887B2/en active Active
- 2017-04-13 EP EP17718870.3A patent/EP3455255B1/en active Active
- 2017-04-13 CA CA3023787A patent/CA3023787A1/en not_active Abandoned
- 2017-04-13 US US15/486,468 patent/US9758583B2/en active Active
- 2017-04-13 KR KR1020187035791A patent/KR20190015715A/ko not_active Ceased
- 2017-04-13 AU AU2017262448A patent/AU2017262448A1/en not_active Abandoned
- 2017-04-13 CN CN201780029330.5A patent/CN109563165B/zh active Active
- 2017-04-13 SG SG11201809857TA patent/SG11201809857TA/en unknown
- 2017-04-13 JP JP2018559329A patent/JP6650537B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519208A5 (OSRAM) | ||
| JP2018508475A5 (OSRAM) | ||
| US11690908B2 (en) | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy | |
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| JP2018500924A5 (OSRAM) | ||
| JP2017536111A5 (OSRAM) | ||
| JP2017538441A5 (OSRAM) | ||
| JP2018527912A5 (OSRAM) | ||
| JP2020533960A (ja) | 抗ｉｌ１ｒａｐ抗体 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| US20190358262A1 (en) | Methods for modulation of car-t cells | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| CN112955179A (zh) | 拮抗性抗肿瘤坏死因子受体超家族多肽 | |
| JP2023073965A (ja) | 癌関連免疫抑制阻害剤 | |
| WO2024182541A1 (en) | Molecules that bind to b-cell activating factor receptor polypeptides | |
| TW202545991A (zh) | 抗ｃｄ２８抗體及其用途 | |
| RU2024115283A (ru) | Композиции vcar и способы применения |